Nasdaq tmdx.
Shares of TransMedics Group ( TMDX 2.02%) were down around 10% by 2:45 p.m. E.T. on Friday after the company announced second-quarter earnings. The healthcare stock is up more than 27% this year ...
Earnings for TransMedics Group are expected to decrease in the coming year, from ($0.34) to ($0.67) per share. TransMedics Group has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 28th, 2024 based off prior year's report dates. Read More.One such superstar is TransMedics Group, Inc. (NASDAQ:TMDX), which saw its share price soar 340% in three years. Also pleasing for shareholders was the 21% gain in the last three months.ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksDec 4, 2023 · Shares of TMDX stock opened at $74.66 on Monday. The stock has a market cap of $2.44 billion, a P/E ratio of -67.87 and a beta of 2.06. TransMedics Group, Inc. has a 12 month low of $36.42 and a ...
ANDOVER, Mass., Nov. 11, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...2023年11月7日 上午10:15 · 16 分鐘文章. TransMedics Group, Inc. (NASDAQ: TMDX) Q3 2023 Earnings Call Transcript November 6, 2023. Operator: Good afternoon, and welcome to TransMedics Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer ...
The forecasts range from a low of 74.74 to a high of $99.75. The average price target represents an increase of 8.75% from its latest reported closing price of 77.85. See our leaderboard of ...ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for ...
NASDAQ:TMDX opened at $74.66 on Friday. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $99.63. The company has a market cap of $2.44 billion, a P/E ratio of ...TransMedics (NASDAQ:TMDX) stock is climbing higher on Tuesday following the release of the company’s earnings report for the third quarter of 2023. Incredibly high revenue of $66.43 million is ...Apr 19, 2022 · ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ... The TransMedics Group Inc. stock price gained 3.88% on the last trading day (Thursday, 30th Nov 2023), rising from $72.85 to $75.68. During the last trading day the stock fluctuated 5.97% from a day low at $72.11 to a day high of $76.42. The price has risen in 7 of the last 10 days and is up by 15.38% over the past 2 weeks.२०२३ अगस्ट २ ... (“TransMedics”) (Nasdaq: TMDX), a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ ...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure ...
According to the issued ratings of 8 analysts in the last year, the consensus rating for TransMedics Group stock is Moderate Buy based on the current 1 hold rating and 7 buy ratings for TMDX. The average twelve-month price prediction for TransMedics Group is $79.83 with a high price target of $110.00 and a low price target of $54.00.
ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients ...Shares of TMDX stock opened at $74.66 on Monday. The stock has a market cap of $2.44 billion, a P/E ratio of -67.87 and a beta of 2.06. TransMedics Group, Inc. has a 12 month low of $36.42 and a ...ANDOVER, Mass., May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023. Recent Highlights Net revenue of …Nov 30, 2023 · See the latest TransMedics Group Inc stock price (TMDX:XNAS), related news, valuation, ... TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Dec 29, 2022 · TransMedics Group, Inc. (NASDAQ:TMDX) is a Massachusetts-based commercial-stage medical technology company, engaged in transforming organ transplant therapy for end-stage organ failure patients in ... Dec 4, 2023 · Shares of TMDX stock opened at $74.66 on Monday. The stock has a market cap of $2.44 billion, a P/E ratio of -67.87 and a beta of 2.06. TransMedics Group, Inc. has a 12 month low of $36.42 and a ...
Stock Exchange NASDAQ Ticker Symbol TMDX Full Company Profile Financial Performance In 2022, TMDX's revenue was $93.46 million, an increase of …ANDOVER, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients ...Nov 10, 2023 · TransMedics (TMDX) reported $66.43 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 158.7%. EPS of -$0.12 for the same period compares to -$0.25 a ... TransMedics Group, Inc. (NASDAQ:TMDX) is a Massachusetts-based commercial-stage medical technology company, engaged in transforming organ transplant therapy for end-stage organ failure patients in ...This medical technology company is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +31.6%. Revenues are expected to be $32.59 ...
TransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028. ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st... 7 months ago - PRNewsWire.
The forecasts range from a low of 74.74 to a high of $99.75. The average price target represents an increase of 8.75% from its latest reported closing price of 77.85. See our leaderboard of ...Nov 30, 2023 · See the latest TransMedics Group Inc stock price (TMDX:XNAS), related news, valuation, ... TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...Based on analysts offering 12 month price targets for TMDX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . ANDOVER, Mass., Feb. 23, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...May 21, 2023 · COGS surged from $9 million in 2020 to $28.2 million in 2022, while operating expenses surged from $43 million in 2020 to $96.7 million in 2022. However, there's some good news in terms of the ... Find the latest dividend history for TransMedics Group, Inc. Common Stock (TMDX) at Nasdaq.com.
Back to TMDX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following …
Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...
TransMedics’ (NASDAQ: TMDX) Organ Care System is utilized “for preserving organs used in the treatment of end-stage heart, lung, and liver failure.”Nov 14, 2023 · TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and ... TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...Find the latest SEC Filings data for TransMedics Group, Inc. Common Stock (TMDX) at Nasdaq.com.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and ...NASDAQ:TMDX opened at $74.66 on Friday. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $99.63. The company has a market cap of $2.44 billion, a P/E ratio of ...२०२२ मे ३ ... TMDX. The Nasdaq Stock Market LLC. ( The Nasdaq Global Market ). Indicate by check mark whether the registrant is an emerging growth company as ...Jul 22, 2022 · Find the latest SEC Filings data for TransMedics Group, Inc. Common Stock (TMDX) at Nasdaq.com. Back to TMDX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following …Target price 65.415. Change. Ends at 07.11.24. TransMedics Group, Inc. (NASDAQ: TMDX) had its price target raised by analysts at JPMorgan Chase & Co. from $67.00 to $70.00. They now have an "overweight" rating on the stock. Ratings data for TMDX provided by MarketBeat.The market capitalization of TMDX is $1.7 billion. TMDX has shown promising earnings growth, with a growth rate of 23.44% in the previous year and 63.95% this year. TMDX’s revenue growth in the last year was remarkable, standing at 208.83%. The Price/Sales ratio for TMDX is 19.52, and the Price/Book ratio is 8.86.In trading on Monday, shares of TransMedics Group Inc (Symbol: TMDX) crossed below their 200 day moving average of $70.28, changing hands as low as $68.37 per share. TransMedics Group Inc shares ...
TransMedics also has just under $60 million in long-term debt as well as some $445 in senior convertible notes. The company netted approximately $393 million from this transaction. The latter was ...TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Monday, November, 6th. The company reported ($0.12) EPS for the quarter, …ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...Dec 16, 2022 · Akarawut Lohacharoenvanich/iStock via Getty Images. Thesis. TransMedics Group, Inc. (NASDAQ:TMDX) has a long runway of growth left ahead of it.Sitting at just under $2B market cap, TransMedics ... Instagram:https://instagram. dividend mutual funds beststock toyotatmfc etfmootly fool The stock options were granted with a per share exercise price of $38.05, the closing price of the common stock on the Nasdaq Global Market on November 1, 2023. Twenty-five percent of the shares ... best futures brokers usatakeada ANDOVER, Mass., Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with ... good day trading penny stocks LivaNova (NASDAQ:LIVN) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the superior business?We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.TransMedics Group, Inc. (NASDAQ:TMDX) has been making waves in the medical technology sector with its organ care system platform development and commercialization. The company has recently earned a consensus rating of “Moderate Buy” from seven brokerages that are currently covering the firm, according to Bloomberg reports.The stock options were granted with a per share exercise price of $38.05, the closing price of the common stock on the Nasdaq Global Market on November 1, 2023. Twenty-five percent of the shares ...